Micar Innovation

Micar Innovation is a private, pre-revenue biotech company providing AI-powered computational drug discovery services and developing its own internal pipeline. Its core technology platform integrates advanced molecular modeling, dynamics, and free energy calculations to de-risk and accelerate early-stage drug discovery, claiming to reduce the timeline for entire discovery processes to 2-8 weeks. The company targets orphan GPCRs, understudied proteins, and rare diseases, and has demonstrated its capabilities through published research on SARS-CoV-2 variants and partnerships for medicinal cosmetics development.

Integrated AI and computational biophysics platform utilizing Free Energy Perturbation (FEP+), classical/accelerated Molecular Dynamics (cMD/aMD), molecular docking, pharmacophore modeling, and bioinformatics for structure-based drug design, ADMET prediction, and target characterization, focused on membrane proteins and orphan GPCRs.

Micar21 competes in the rapidly growing AI-driven drug discovery sector against companies like Schrödinger, Exscientia, Recursion, and Atomwise. Its differentiation lies in its deep focus on advanced molecular dynamics and FEP+ calculations for difficult targets, but it must contend with competitors possessing greater financial resources, broader datasets, and more advanced clinical pipelines.